Skip to Main Content

Paper Details

Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.
Nat Med
5
2020
leptomeningeal carcinomatosis, patients
Author NameAffiliation
Priscilla K BrastianosMassachusetts General Hospital, Harvard Medical School
Sara M TolaneyDana-Farber Cancer Institute, Harvard Medical School
Nancy U LinDana-Farber Cancer Institute, Harvard Medical School
Nancy WangMassachusetts General Hospital, Harvard Medical School
Ian E KropDana-Farber Cancer Institute, Harvard Medical School
Brian V NahedMassachusetts General Hospital, Harvard Medical School
Tracy T BatchelorMassachusetts General Hospital, Harvard Medical School
Tracy T BatchelorMassachusetts General Hospital, Harvard Medical School
Helen A ShihMassachusetts General Hospital, Harvard Medical School
Scott L CarterDana-Farber Cancer Institute, Harvard Medical School
  • 1 - 10

Datasets

Release 1.2